Biomarkers Market - Trends Forecast Till 2028

Market Overview

The global biomarkers market size was valued at USD 43.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 12.6% from 2021 to 2028.

Diagnostic biomarkers are minimally or non-invasive tools. Biomarkers, integrated with key imaging and data management technologies, is meeting the market expectations; however, has set backs too. Biomarkers are used in imaging technology to provide clear imaging of oncology tumours and other problems and also eliminate chance of radiation exposure during imaging through CT scan and MRI scan.

The growing importance of companion diagnostics, increasing prevalence of cancer worldwide, increasing funds & grants for biomarker research, and continuous product innovations are some of the factors that have supported long-term expansion for Biomarkers Market.

Many biomarkers are also playing an important role in the diagnosis of COVID-19. Biomarkers such as C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, renal biomarkers, lymphocytes and platelet count. These markers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts.

Regional Analysis

North America accounted for the largest share of the market. The large share of this region can be attributed to the growing use of biomarkers in personalized medicine, various growth strategies adopted by key players with established pharmaceutical companies in this region, and a higher adoption rate of biomarkers for disease diagnostics, majorly in cancer diagnosis.

Insights are provided for each region and major countries within the regions

Competitive Landscape

Key Players

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• QIAGEN N.V.
• PerkinElmer, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Enzo Biochem, Inc.
• Charles River Laboratories International, Inc.
• Eurofins Scientific

Recent Developments

• In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched two cardiac biomarker tests for high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers support cardiovascular disease management and can help clinicians diagnose heart attacks and manage heart failure better.
• In May 2021, QIAGEN N.V. (Netherlands) launched the first FDA-approved tissue companion diagnostic, therascreen KRAS RGQ PCR Kit, to identify the KRAS G12C mutation in NSCLC tumors and expand precision medicine options in lung cancer.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
• Gain authentic and granular data access for Biomarkers Market so as to understand the trends and the factors involved behind changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope